Cargando…
Clinical Impact of Lymphadenectomy after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Review of Available Data
Recent robust data allow for omitting lymph node dissection for patients with advanced epithelial ovarian cancer (EOC) and without any suspicion of lymph node metastases, without compromising recurrence-free survival (RFS), nor overall survival (OS), in the setting of primary surgical treatment. Evi...
Autores principales: | Seidler, Stephanie, Koual, Meriem, Achen, Guillaume, Bentivegna, Enrica, Fournier, Laure, Delanoy, Nicolas, Nguyen-Xuan, Huyên-Thu, Bats, Anne-Sophie, Azaïs, Henri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830759/ https://www.ncbi.nlm.nih.gov/pubmed/33477449 http://dx.doi.org/10.3390/jcm10020334 |
Ejemplares similares
-
A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer
por: Métairie, Marie, et al.
Publicado: (2023) -
D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy
por: Shrikhande, Shailesh V, et al.
Publicado: (2013) -
Role of Lymphadenectomy During Interval Debulking Surgery Performed After Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer
por: He, Minjun, et al.
Publicado: (2021) -
Environmental chemicals, breast cancer progression and drug resistance
por: Koual, Meriem, et al.
Publicado: (2020) -
Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report
por: Montero-Macias, Rosa, et al.
Publicado: (2021)